AMPK AND SIRT1 IN THE REGULATION OF LIVER METABOLISM IN OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS

2021 ◽  
Author(s):  
Мария Александровна Вульф ◽  
Дарья Александровна Скуратовская ◽  
Александра Андреевна Комар ◽  
Лариса Сергеевна Литвинова
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Transcription Factor ◽  
Carbohydrate Metabolism ◽  
Liver Metabolism ◽  
Protective Role ◽  
Obese Patients

У больных ожирением выявлены взаимосвязи основных регуляторов метаболизма (AMPK и SITRT1) в печени с нарушениями со стороны липидного и углеводного обменов. Установлена протекторная роль SIRT1 в подавлении экспрессии транскрипционного фактора NF-kB в печени, способствующего переходу стеатоза в стеатогепатит. In obese patients, interrelations of the main regulators of metabolism (AMPK and SITRT1) in the liver with lipid and carbohydrate metabolism disorders were revealed. The protective role of SIRT1 in suppressing the expression of the transcription factor NF-kB in the liver, which promotes the transition of steatosis to steatohepatitis, has been established.

Protective role of calcium ion against stress-induced osmotic fragility of red blood cells in patients with type 2 diabetes mellitus

2013 ◽  
Vol 53 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Ebrahim Mostafavi ◽  
Manouchehr Nakhjavani ◽  
Zaniar Ghazizadeh ◽  
Hassan Barakati ◽  
Hossein Mirmiranpour ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Red Blood Cells ◽  
Calcium Ion ◽  
Blood Cells ◽  
Osmotic Fragility ◽  
Protective Role

scholarly journals The importance of glycemic control in patients with early forms of carbohydrate metabolism disorders in order to prevent type 2 diabetes mellitus and cardiovascular pathology

2020 ◽  
Vol 22 (12) ◽  
pp. 57-62
Author(s):  
Irina I. Kochergina ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Carbohydrate Metabolism ◽  
Vascular Complications ◽  
Cardiovascular Complications ◽  
Cardiovascular Pathology

The article presents data on the prevalence of diabetes and prediabetes; the high compatibility of diabetes mellitus and cardiovascular pathology; high mortality among patients with diabetes mellitus and coronary heart disease, in the presence of both acute and chronic cardiovascular complications; on the important role of glucose- and lipotoxicity in the progression of carbohydrate metabolism from prediabetes to type 2 diabetes mellitus, the role of hyperglycemia in the deve-lopment of insulin resistance, atherosclerosis, hypertension, liver, kidney, endothelial dysfunction, the role of hyper- and hypoglycemia in the development of acute vascular complications – myocardial infarction, stroke, gangrene of the lower extremities; on the protective role of adiponectin – a predictor of type 2 diabetes mellitus, on the importance of glycemic control for the timely detection of early disorders of carbohydrate metabolism – impaired glucose tolerance and impaired fasting glucose; on the role of metformin in the prevention of progression of prediabetes to type 2 diabetes and cardiac pathology; on the gluco- and cardioprotective role of modern sugar-lowering drugs.

scholarly journals Type 2 diabetes mellitus and gout

2021 ◽  
Vol 59 (5) ◽  
pp. 599-607
Author(s):  
O. V. Zhelyabina ◽  
M. S. Eliseev
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Uric Acid ◽  
Carbohydrate Metabolism ◽  
Metabolic Diseases ◽  
Metabolic Effects ◽  
Stress Damage

Gout is the most common inflammatory arthritis in adults and has continued to increase in prevalence over the past decades. Gout is characterized by hyperuricemia with the obligatory crystallization of urates and an associated inflammatory reaction, as well as metabolic effects caused, among other things, by these processes. In particular, the diagnosis of gout is identified with a high risk of carbohydrate metabolism disorders, which is 2 times higher than the population risk: according to various sources, from 21 to 26% of patients with gout have type 2 diabetes mellitus (DM 2). However, the role of uric acid and urate-lowering drugs in its development in patients with gout remains controversial. The possibility of influencing the risk of developing diabetes mellitus type 2 of chronic inflammation, the activity of interleukin-1β and other pro-inflammatory cytokines, hyperuricemia, xanthioxidase and other factors associated with gout is discussed. It is possible that the level of uric acid is associated with diabetes and other metabolic diseases, causing pathophysiological changes not only through inflammation, but also oxidative stress, damage to the vascular endothelium. It is also suggested that gout and DM 2 may share genetic markers. The interrelation of violations of purine and carbohydrate metabolism prompts the search for drugs that have a simultaneous positive effect on purine and carbohydrate metabolism. However, it is not clear what the level of uric acid should be considered as a risk factor, there are conflicting data on the possibility of reducing the risk of developing diabetes with various anti-gout therapies.

Sign in / Sign up

Export Citation Format

Share Document